Showing results (141-150 of 205) with videos related to

Sort By:
Pageof 21
Drugs in R&D|April 2, 2025
Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab BiosimilarHerve Bischoff, Neil K O'Connor, Jamie Kim, et al.
Bulletin Du Cancer|June 6, 2012
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]Anne-Claire Hardy-Bessard, Rémy Delva, Xavier Pivot, et al.
Oncotargets and Therapy|March 7, 2014
Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinomaVirginie Nerich, Marion Hugues, Marie Justine Paillard, et al.
International Journal of Clinical Oncology|July 6, 2012
Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?Erion Dobi, Fernando Bazan, Armelle Dufresne, et al.
Transfusion|July 13, 2021
Impact of COVID-19 and lockdown regarding blood transfusionXavier Delabranche, Daniel Kientz, Charles Tacquard, et al.
Breast Cancer Research and Treatment|June 8, 2019
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokineticsVéronique Diéras, Hervé Bonnefoi, Emilio Alba, et al.
British Journal of Clinical Pharmacology|January 6, 2011
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patientsMarie-Christine Etienne-Grimaldi, Patricia Formento, Armelle Degeorges, et al.
Medicine and Science in Sports and Exercise|June 27, 2024
Impact of Eccentric versus Concentric Cycling Exercise on Neuromuscular Fatigue and Muscle Damage in Breast Cancer PatientsElyse Hucteau, Joris Mallard, Chiara Barbi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE StudyEdith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.
Oncology Reports|February 11, 2017
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case reportGuillaume Meynard, Laura Mansi, Pierre Lebahar, et al.
Pageof 21